Current market catalysts

8-K filing — SailPoint, Inc. (SAIL)

Filed: 2026-09-09 AccNo: 0001628280-26-061015 Size: 639 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

LifeStance Health Announces 22.25M Share Secondary Offering By Selling Stockholders; Announces Concurrent Buyback Of 2M Shares From Underwriter, Receives No Proceeds

Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint

Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey secondary endpoint also

Needham Reiterates Buy on IonQ, Maintains $65 Price Target

Needham analyst N. Quinn Bolton reiterates IonQ (NYSE:IONQ) with a Buy and maintains $65 price target.

U.S. Bank Announces Live Pilot Cross-Border Payment Between Its North America And Europe Entities Using USBDC Dollar-Backed Stablecoin On Stellar Blockchain

Sunbelt Rentals Holdings Raises FY2027 Sales Guidance from $11.652B-$11.986B to $11.819B-$12.154B vs $11.906B Est

Sunbelt Rentals Holdings (NYSE:SUNB) raises FY2027 sales outlook from $11.652 billion-$11.986 billion to $11.819 billion-$12.154 billion vs $11.906 billion estimate.

Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Challenge Study Of CDI-988; Says No Serious Adverse Events To Date, Preliminary Efficacy Results Expected Late 2026 Or Early 2027

Nasdaq Grants Iveda Additional 180-Calendar-Day Period, Through March 1, 2027, To Regain Compliance With Nasdaq's Minimum Bid Price Requirement

Extension provides additional time through March 1, 2027, as Iveda advances commercial execution across its AI and connected-technology portfolioIveda® (NASDAQ:IVDA),a global provider of AI-powered video intelligence,

8-K filing — Tyra Biosciences, Inc. (TYRA)

Filed: 2026-09-09 AccNo: 0001193125-26-385886 Size: 168 KB Item 8.01: Other Events

Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models

The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis

The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the

Cantor Fitzgerald Reiterates Overweight on IonQ, Maintains $70 Price Target

Cantor Fitzgerald analyst Troy Jensen reiterates IonQ (NYSE:IONQ) with a Overweight and maintains $70 price target.

8-K filing — Sunbelt Rentals Holdings, Inc. (SUNB)

Filed: 2026-09-09 AccNo: 0001628280-26-061014 Size: 545 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

CORRECTION: Signet Jewelers Raises FY2027 Adj EPS Guidance from $9.20-$11.00 to $10.45-$12.15 vs $10.82 Est; Affirms FY2027 Sales Guidance of $6.700B-$6.900B vs $6.841B Est

Signet Jewelers (NYSE:SIG) raises FY2027 Adj EPS guidance from $9.20-$11.00 to $10.45-$12.15 vs $10.82 analyst estimate. Affirms FY2027 sales outlook from $6.700 billion-$6.900 billion to $6.700 billion-$6.900 billion

Coinbase Partners With Trading And Workflow Automation Software Provider ION To Support Event Contract Clearing For Kalshi

Event Contracts is ION's latest extension to its flagship XTP solution, offering a fully automated, real-time platform for the creation, resolution, and settlement of event-based contracts. It provides Coinbase with

Lightbridge Announces Second Project Task Statement With Battelle Energy Alliance Securing Idaho National Laboratory Advanced Test Reactor Loop Access For Irradiation Of Clad Fuel Rodlets

Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with

Chewy Sees Q3 Sales $3.323B-$3.358B vs $3.332B Est

Chewy (NYSE:CHWY) sees Q3 sales of $3.323 billion-$3.358 billion vs $3.332 billion analyst estimate.

Kura Oncology Announces Launch Of Caspian Therapeutics With $50M Financing Led By BVF Partners, With Eli Lilly Participating, To Advance Menin Inhibitor KO-7246 In Diabetes; Retains About Half Ownership

Chewy Raises FY2026 Sales Guidance from $13.400B-$13.550B to $13.460B-$13.570B vs $13.553B Est

Chewy (NYSE:CHWY) raises FY2026 sales outlook from $13.400 billion-$13.550 billion to $13.460 billion-$13.570 billion vs $13.553 billion estimate.

Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.

Fars Media Citing An IRGC Spokesperson Says Restricted Maritime Area Extends From Chabahar Into Parts Of Gulf Of Oman And Arabian Sea; Ships Transiting Hormuz Without Coordination Face Sanctions

- Reuters

Xanadu Quantum And ASML Collaborate To Develop Advanced Lithography Processes For Xanadu’s Photonic Quantum Hardware

Xanadu Quantum Technologies Limited ((", Xanadu", , TSX:XNDU), a leading photonic quantum computing company, and ASML, a leading supplier to the semiconductor industry, today announced a collaboration to develop

Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in

Chewy Q2 Adj. EPS $0.36, Inline, Sales $3.330B Miss $3.361B Estimate

Chewy (NYSE:CHWY) reported quarterly earnings of $0.36 per share which met the analyst consensus estimate. This is a 9.09 percent increase over earnings of $0.33 per share from the same period last year. The company

Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed

OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual

Corteva Announces Definitive Agreement To Form 50/50 Crop Protection Joint Venture With Globachem; Expects Close In Q4 2026

8-K filing — Kura Oncology, Inc. (KURA)

Filed: 2026-09-09 AccNo: 0001193125-26-385881 Size: 142 KB Item 8.01: Other Events

ODDITY Tech Sees Q3 Sales $140.505M vs $122.639M Est

ODDITY Tech (NASDAQ:ODD) sees Q3 sales of $140.505 million vs $122.639 million analyst estimate.

8-K filing — Chewy, Inc. (CHWY)

Filed: 2026-09-09 AccNo: 0001628280-26-061011 Size: 490 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits